Arrowhead Pharmaceuticals Stock Price To Book

ARWR Stock

USD 23.91 0.78 3.16%

Arrowhead Pharmaceuticals fundamentals help investors to digest information that contributes to Arrowhead Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Arrowhead Stock. The fundamental analysis module provides a way to measure Arrowhead Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arrowhead Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

As of 06/10/2024, Price To Book Ratio is likely to drop to 4.80.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arrowhead Pharmaceuticals Company Price To Book Analysis

Arrowhead Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Arrowhead Pharmaceuticals Price To Book

19.08 X

Most of Arrowhead Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arrowhead Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arrowhead Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Arrowhead Pharmaceuticals is extremely important. It helps to project a fair market value of Arrowhead Stock properly, considering its historical fundamentals such as Price To Book. Since Arrowhead Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arrowhead Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arrowhead Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Long Term Debt	Property Plant Equipment	Good Will	Short Term Investments	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.78	0.04	-0.92	0.79	0.24	0.92	0.53	0.74	0.26	0.36	0.62	0.83	0.2	0.97	0.03	0.77	0.42	0.98	0.26	-0.22	0.93	0.11	0.72	0.72	0.26
Total Stockholder Equity	0.78		-0.4	-0.63	0.54	0.37	0.48	0.64	0.51	-0.14	0.39	0.55	0.48	0.25	0.66	0.17	0.8	0.37	0.74	0.26	-0.3	0.72	0.16	0.95	0.69	-0.14
Net Debt	0.04	-0.4		-0.17	0.32	-0.38	0.29	-0.62	0.04	0.12	-0.62	-0.07	0.43	-0.2	0.27	-0.28	-0.33	-0.03	0.09	-0.15	0.28	0.22	-0.16	-0.34	-0.29	0.13
Retained Earnings	-0.92	-0.63	-0.17		-0.78	-0.09	-0.9	-0.41	-0.69	-0.3	-0.23	-0.75	-0.83	-0.44	-0.92	-0.24	-0.63	-0.56	-0.95	-0.43	0.36	-0.86	-0.21	-0.55	-0.57	-0.29
Accounts Payable	0.79	0.54	0.32	-0.78		-0.14	0.76	-0.06	0.84	-0.16	-0.17	0.52	0.97	0.16	0.81	0.02	0.28	0.33	0.78	0.27	-0.08	0.91	0.09	0.47	0.19	-0.16
Net Receivables	0.24	0.37	-0.38	-0.09	-0.14		0.12	0.55	-0.14	0.03	0.74	0.1	-0.15	0.03	0.1	0.0	0.4	0.21	0.15	0.04	-0.14	0.21	-0.03	0.44	0.41	0.03
Total Liab	0.92	0.48	0.29	-0.9	0.76	0.12		0.37	0.72	0.46	0.27	0.53	0.86	0.13	0.95	-0.06	0.6	0.36	0.91	0.2	-0.13	0.85	0.06	0.43	0.59	0.46
Total Current Assets	0.53	0.64	-0.62	-0.41	-0.06	0.55	0.37		0.11	0.5	0.85	0.4	-0.01	0.29	0.38	0.22	0.87	0.32	0.51	0.26	-0.33	0.24	0.16	0.61	0.87	0.49
Short Term Debt	0.74	0.51	0.04	-0.69	0.84	-0.14	0.72	0.11		-0.05	0.12	0.47	0.84	0.09	0.71	-0.04	0.35	0.29	0.71	0.14	-0.06	0.75	0.02	0.48	0.31	-0.05
Common Stock	0.26	-0.14	0.12	-0.3	-0.16	0.03	0.46	0.5	-0.05		0.42	0.13	0.03	0.07	0.31	-0.02	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.54	1.0
Current Deferred Revenue	0.36	0.39	-0.62	-0.23	-0.17	0.74	0.27	0.85	0.12	0.42		0.28	-0.13	0.19	0.19	0.15	0.61	0.28	0.3	0.18	-0.18	0.12	0.05	0.43	0.69	0.41
Long Term Debt	0.62	0.55	-0.07	-0.75	0.52	0.1	0.53	0.4	0.47	0.13	0.28		0.49	0.58	0.58	0.49	0.48	0.84	0.72	0.79	-0.52	0.55	0.02	0.48	0.48	0.13
Property Plant Equipment	0.83	0.48	0.43	-0.83	0.97	-0.15	0.86	-0.01	0.84	0.03	-0.13	0.49		0.08	0.89	-0.09	0.34	0.3	0.83	0.16	-0.06	0.91	0.04	0.43	0.28	0.03
Good Will	0.2	0.25	-0.2	-0.44	0.16	0.03	0.13	0.29	0.09	0.07	0.19	0.58	0.08		0.15	0.96	0.17	0.52	0.31	0.64	-0.45	0.15	0.72	0.19	0.17	0.07
Short Term Investments	0.97	0.66	0.27	-0.92	0.81	0.1	0.95	0.38	0.71	0.31	0.19	0.58	0.89	0.15		-0.03	0.68	0.39	0.97	0.2	-0.15	0.93	0.08	0.62	0.65	0.31
Intangible Assets	0.03	0.17	-0.28	-0.24	0.02	0.0	-0.06	0.22	-0.04	-0.02	0.15	0.49	-0.09	0.96	-0.03		0.03	0.42	0.14	0.59	-0.42	-0.01	0.73	0.1	0.09	-0.02
Net Tangible Assets	0.77	0.8	-0.33	-0.63	0.28	0.4	0.6	0.87	0.35	0.4	0.61	0.48	0.34	0.17	0.68	0.03		0.32	0.75	0.2	-0.32	0.56	0.05	0.79	0.9	0.4
Long Term Debt Total	0.42	0.37	-0.03	-0.56	0.33	0.21	0.36	0.32	0.29	0.13	0.28	0.84	0.3	0.52	0.39	0.42	0.32		0.47	0.76	-0.42	0.37	-0.13	0.39	0.38	0.13
Capital Surpluse	0.98	0.74	0.09	-0.95	0.78	0.15	0.91	0.51	0.71	0.3	0.3	0.72	0.83	0.31	0.97	0.14	0.75	0.47		0.35	-0.29	0.9	0.15	0.67	0.71	0.3
Deferred Long Term Liab	0.26	0.26	-0.15	-0.43	0.27	0.04	0.2	0.26	0.14	0.08	0.18	0.79	0.16	0.64	0.2	0.59	0.2	0.76	0.35		-0.28	0.21	0.03	0.22	0.21	0.08
Accumulated Depreciation	-0.22	-0.3	0.28	0.36	-0.08	-0.14	-0.13	-0.33	-0.06	-0.09	-0.18	-0.52	-0.06	-0.45	-0.15	-0.42	-0.32	-0.42	-0.29	-0.28		-0.12	-0.26	-0.16	-0.2	-0.09
Long Term Investments	0.93	0.72	0.22	-0.86	0.91	0.21	0.85	0.24	0.75	-0.03	0.12	0.55	0.91	0.15	0.93	-0.01	0.56	0.37	0.9	0.21	-0.12		0.09	0.69	0.47	-0.03
Short Long Term Debt	0.11	0.16	-0.16	-0.21	0.09	-0.03	0.06	0.16	0.02	0.02	0.05	0.02	0.04	0.72	0.08	0.73	0.05	-0.13	0.15	0.03	-0.26	0.09		0.06	0.07	0.02
Net Invested Capital	0.72	0.95	-0.34	-0.55	0.47	0.44	0.43	0.61	0.48	-0.16	0.43	0.48	0.43	0.19	0.62	0.1	0.79	0.39	0.67	0.22	-0.16	0.69	0.06		0.7	-0.16
Net Working Capital	0.72	0.69	-0.29	-0.57	0.19	0.41	0.59	0.87	0.31	0.54	0.69	0.48	0.28	0.17	0.65	0.09	0.9	0.38	0.71	0.21	-0.2	0.47	0.07	0.7		0.54
Capital Stock	0.26	-0.14	0.13	-0.29	-0.16	0.03	0.46	0.49	-0.05	1.0	0.41	0.13	0.03	0.07	0.31	-0.02	0.4	0.13	0.3	0.08	-0.09	-0.03	0.02	-0.16	0.54

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Arrowhead Pharmaceuticals

Price Book Value Ratio Over Time

Arrowhead Book Value Per Share

Book Value Per Share

2.4

At this time, Arrowhead Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year.

Based on the latest financial disclosure, Arrowhead Pharmaceuticals has a Price To Book of 19.0781 times. This is 25.71% lower than that of the Biotechnology sector and 215.86% higher than that of the Health Care industry. The price to book for all United States stocks is 100.61% lower than that of the firm.

Arrowhead Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.

Arrowhead Pharmaceuticals is currently under evaluation in price to book category among its peers.

Arrowhead Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Arrowhead Pharmaceuticals from analyzing Arrowhead Pharmaceuticals' financial statements. These drivers represent accounts that assess Arrowhead Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arrowhead Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	1.6B	2.6B	4.3B	3.5B	3.1B	3.3B
Enterprise Value	1.6B	2.4B	4.2B	3.5B	3.1B	3.3B

Arrowhead Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arrowhead Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arrowhead Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Arrowhead Fundamentals

	Return On Equity	-0.99
	Return On Asset	-0.32
	Operating Margin	(13.36) %
	Current Valuation	2.86 B
	Shares Outstanding	124.2 M
	Shares Owned By Insiders	4.47 %
	Shares Owned By Institutions	79.52 %
	Number Of Shares Shorted	9.34 M
	Price To Earning	482.39 X
	Price To Book	19.08 X
	Price To Sales	16.84 X
	Revenue	240.74 M
	Gross Profit	240.74 M
	EBITDA	(188.16 M)
	Net Income	(209.28 M)
	Cash And Equivalents	416.5 M
	Cash Per Share	3.93 X
	Total Debt	115.17 M
	Debt To Equity	0.17 %
	Current Ratio	3.37 X
	Book Value Per Share	3.90 X
	Cash Flow From Operations	(153.89 M)
	Short Ratio	8.67 X
	Earnings Per Share	(4.23) X
	Price To Earnings To Growth	(1.32) X
	Target Price	52.43
	Number Of Employees	525
	Beta	0.94
	Market Capitalization	2.97 B
	Total Asset	765.55 M
	Retained Earnings	(1.03 B)
	Working Capital	110.03 M
	Current Asset	90.5 M
	Current Liabilities	25.64 M
	Net Asset	765.55 M

About Arrowhead Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC